Diagnostic RET genetic testing in 1,058 index patients : A UK centre perspective
© 2021 John Wiley & Sons Ltd..
OBJECTIVE: Diagnostic germline RET analysis is offered to all patients with a diagnosis of medullary thyroid carcinoma (MTC), or other conditions associated with multiple endocrine neoplasia type 2 (MEN2) in the United Kingdom. Here, we report the experience of a single centre's germline RET analysis over a 21-year period.
DESIGN: Retrospective case-note review.
PATIENTS: All index patients referred to the Exeter Genomics Laboratory for diagnostic germline RET analysis between 1997 and 2018, and unaffected family members, undergoing predictive testing.
MEASUREMENTS: The rate and nature of pathogenic variant detection were recorded, as well as the indication for testing.
RESULTS: 1,058 index patients and 551 unaffected family members were tested. The overall rate of pathogenic variant detection was 10.2% amongst index patients and 29% amongst unaffected family members. The commonest indication was isolated MTC, and amongst the 690 patients with isolated MTC, 68 (9.9%) were found to harbour a RET pathogenic variant. Of those with presumed sporadic MTC, 8.5% were found to harbour germline RET pathogenic variants, compared with 36.4% of those with a family history of MEN2-associated conditions. Pathogenic variants were identified in 3.6% and 0% of patients with isolated phaeochromocytoma and primary hyperparathyroidism, respectively.
CONCLUSIONS: Although the detection rate of RET germline pathogenic variants in patients with presumed sporadic MTC was significant, the overall detection rate in those with MTC was lower than expected in this series. Advances in RET analysis in response to reports of new variants over the last two decades are likely to have improved the pick-up rate in recent years.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Clinical endocrinology - 95(2021), 2 vom: 01. Aug., Seite 295-302 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fussey, Jonathan Mark [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.10.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cen.14395 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319052788 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319052788 | ||
| 003 | DE-627 | ||
| 005 | 20231225170635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cen.14395 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319052788 | ||
| 035 | |a (NLM)33340421 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fussey, Jonathan Mark |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic RET genetic testing in 1,058 index patients |b A UK centre perspective |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVE: Diagnostic germline RET analysis is offered to all patients with a diagnosis of medullary thyroid carcinoma (MTC), or other conditions associated with multiple endocrine neoplasia type 2 (MEN2) in the United Kingdom. Here, we report the experience of a single centre's germline RET analysis over a 21-year period | ||
| 520 | |a DESIGN: Retrospective case-note review | ||
| 520 | |a PATIENTS: All index patients referred to the Exeter Genomics Laboratory for diagnostic germline RET analysis between 1997 and 2018, and unaffected family members, undergoing predictive testing | ||
| 520 | |a MEASUREMENTS: The rate and nature of pathogenic variant detection were recorded, as well as the indication for testing | ||
| 520 | |a RESULTS: 1,058 index patients and 551 unaffected family members were tested. The overall rate of pathogenic variant detection was 10.2% amongst index patients and 29% amongst unaffected family members. The commonest indication was isolated MTC, and amongst the 690 patients with isolated MTC, 68 (9.9%) were found to harbour a RET pathogenic variant. Of those with presumed sporadic MTC, 8.5% were found to harbour germline RET pathogenic variants, compared with 36.4% of those with a family history of MEN2-associated conditions. Pathogenic variants were identified in 3.6% and 0% of patients with isolated phaeochromocytoma and primary hyperparathyroidism, respectively | ||
| 520 | |a CONCLUSIONS: Although the detection rate of RET germline pathogenic variants in patients with presumed sporadic MTC was significant, the overall detection rate in those with MTC was lower than expected in this series. Advances in RET analysis in response to reports of new variants over the last two decades are likely to have improved the pick-up rate in recent years | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a c-ret proto-oncogene proteins | |
| 650 | 4 | |a genetic testing | |
| 650 | 4 | |a medullary carcinoma | |
| 650 | 4 | |a multiple endocrine neoplasia type 2a | |
| 650 | 4 | |a multiple endocrine neoplasia type 2b | |
| 650 | 4 | |a phaeochromocytoma | |
| 650 | 4 | |a primary hyperparathyroidism | |
| 650 | 7 | |a MAS1 protein, human |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Mas |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a RET protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Smith, Joel Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Cleaver, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Bowles, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Ellard, Sian |e verfasserin |4 aut | |
| 700 | 1 | |a Vaidya, Bijay |e verfasserin |4 aut | |
| 700 | 1 | |a Owens, Martina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical endocrinology |d 1972 |g 95(2021), 2 vom: 01. Aug., Seite 295-302 |w (DE-627)NLM000089117 |x 1365-2265 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2021 |g number:2 |g day:01 |g month:08 |g pages:295-302 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cen.14395 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2021 |e 2 |b 01 |c 08 |h 295-302 | ||